Kyowa Kirin Co., Ltd. (TYO:4151)
2,885.00
+72.50 (2.58%)
At close: Feb 27, 2026
Kyowa Kirin Revenue
In the year 2025, Kyowa Kirin had annual revenue of 496.83B JPY with 0.26% growth. Kyowa Kirin had revenue of 147.38B in the quarter ending December 31, 2025, with 11.01% growth.
Revenue
496.83B
Revenue Growth
+0.26%
P/S Ratio
3.04
Revenue / Employee
87.64M
Employees
5,669
Market Cap
1.51T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 496.83B | 1.27B | 0.26% |
| Dec 31, 2024 | 495.56B | 53.33B | 12.06% |
| Dec 31, 2023 | 442.23B | 43.86B | 11.01% |
| Dec 31, 2022 | 398.37B | 46.13B | 13.09% |
| Dec 31, 2021 | 352.25B | 33.89B | 10.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.47T |
| Astellas Pharma | 2.06T |
| Daiichi Sankyo Company | 2.05T |
| Chugai Pharmaceutical | 1.26T |
| Ono Pharmaceutical | 509.35B |
| Santen Pharmaceutical | 287.99B |
| JCR Pharmaceuticals | 37.55B |
| Perseus Proteomics | 140.41M |
Kyowa Kirin News
- 4 weeks ago - Amgen (AMGN) Ends Collaboration with Kyowa Kirin on Roctinlimab - GuruFocus
- 4 weeks ago - Amgen ends collaboration agreement with Kyowa Kirin for eczema asset - Seeking Alpha
- 4 weeks ago - Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends - Benzinga
- 4 weeks ago - Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends - Benzinga
- 4 weeks ago - Amgen Inc. (AMGN) Announces Termination of License and Collaboration Agreement with Kyowa Kirin - GuruFocus
- 4 weeks ago - Amgen, Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab - Nasdaq
- 4 weeks ago - Amgen (AMGN) Ends Collaboration with Kyowa Kirin on Rocatinlimab - GuruFocus
- 2 months ago - Kyowa Kirin Announces Proposed Appointment of Abdul Mullick to President and Chief Executive Officer, While Former CEO Masashi Miyamoto to Remain Chairman - Business Wire